Pandorum Technologies, a Bengaluru-based biotech startup, has raised $18 million (about ₹150 crore) in a Series B funding round, strengthening India’s regenerative medicine ecosystem. The round was led by Protons Corporate and saw participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund and members of the Burman family.
Funds to accelerate clinical development, regulatory readiness and manufacturing
The fresh capital will be deployed across clinical development, regulatory capability building and expansion of manufacturing infrastructure. Pandorum says a significant portion will support late-stage clinical trials and systems needed for future commercialisation, enabling the company to move investigational therapies through the regulatory pathway more efficiently.
To support global supply and market access, Pandorum has been broadening its manufacturing footprint. It has partnered with AGC Biologics in Italy to serve the US and European markets, and with Nucelion Therapeutics — a Bharat Biotech subsidiary — to strengthen manufacturing and distribution in the Asia‑Pacific region. The company is also exploring additional manufacturing and distribution partnerships in the Middle East.
Pipeline focused on disease‑modifying regenerative therapies
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates at the intersection of biology, engineering and computation. Its platform centres on exosome‑based regenerative therapies designed to reprogram diseased tissues by reducing inflammation, fibrosis and cellular dysfunction rather than solely addressing symptoms.
One of the company’s lead programmes, Kuragenx, is an ophthalmic therapy targeting rare ocular surface disorders such as Stevens‑Johnson syndrome and neurotrophic keratitis. Kuragenx has received Orphan Drug Designation from the US Food and Drug Administration, signalling regulatory recognition of its potential to meet unmet needs in rare eye diseases.
Beyond ophthalmology, Pandorum is extending its regenerative platform to chronic inflammatory and degenerative conditions affecting organs including the lungs, liver and nervous system, reflecting a broader strategy to develop disease‑modifying treatments across multiple therapeutic areas.
Investor confidence and scientific collaborations
Investor participation in the Series B reflects growing confidence in Pandorum’s scientific approach and commercial potential. The financing was structured with strategic advice from Bandana Kankani to align the company’s innovation roadmap with long‑term value creation.
Pandorum’s research and clinical development programmes are supported by collaborations with established clinicians and institutions, including Dr. Shroff’s Charity Eye Hospital in India, Kyoto Prefectural University of Medicine and Northwestern Medicine, which provide clinical expertise and access to patient populations for trials.
Implications for India’s biotech ambitions
The successful Series B round underscores India’s advancing capabilities in advanced biologics and regenerative medicine. By combining academic and clinical partnerships with scalable manufacturing arrangements, Pandorum aims to position itself as a competitive global developer of next‑generation therapeutics.
With additional funding secured, the company will accelerate key programmes, expand internationally and progress towards making regenerative treatments more widely available, reinforcing India’s emergence in the global life‑sciences landscape.
